Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences Initiates Late-Stage Testing of Its Promising Coronavirus Drug

By Keith Speights - Feb 26, 2020 at 6:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company is moving at lightning speed to determine if its experimental drug is safe and effective at treating coronavirus disease COVID-19.

Gilead Sciences (GILD -0.47%) announced Wednesday evening that it's initiating two late-stage clinical studies to evaluate its experimental antiviral drug remdesivir in treating adults diagnosed with coronavirus disease COVID-19.

The biotech company stated that it plans to enroll around 1,000 patients in these studies beginning in March. The patients will primarily be in Asian countries, but Gilead will also include patients from other countries across the world that have been hit hard by the coronavirus outbreak.

Moving quickly

It's practically unheard of for a drugmaker to advance to late-stage clinical studies of an experimental drug as quickly as Gilead is doing, but the urgency of the coronavirus epidemic has paved the way for much faster clinical progress than usually happens.

The company first announced that it was considering remdesivir for treating the coronavirus disease in late January. Remdesivir was initially developed as a treatment for Ebola virus infection, but has shown promise in targeting coronaviruses.

Female healthcare professional holding a mask over her face while holding a vial of blood with a label with "Coronavirus" printed on it

Image source: Getty Images.

Gilead already has several early stage clinical studies of remdesivir underway for treating COVID-19. The company is evaluating the antiviral drug in two studies in China, and recently began a study in the U.S. that's being led by the National Institute of Allergy and Infectious Diseases (NIAID).

What's next

It probably won't take very long for initial results from the late-stage studies that Gilead plans to start in March. Both studies will administer remdesivir over 5-day and 10-day dosing regimens, and will monitor patients' health for 14 days.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$66.02 (-0.47%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.